silevertinib monotherapy

Drug identity checked against registry records

Also recorded as BDTX-1535

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsNCT05256290BDTXPhase 1, Phase 2Recruiting2028-03Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.